Latest News and Press Releases
Want to stay updated on the latest news?
-
REDWOOD CITY, Calif., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the company will report its fourth quarter and full year 2015...
-
REDWOOD CITY, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on February 1, 2016, the compensation committee of the...
-
REDWOOD CITY, Calif., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the 18th Annual BIO...
-
Relypsa reports results from Phase 1 in vivo studies in healthy volunteers evaluating potential drug-drug interactions between Veltassa and 12 drugs administered either at the same time or...
-
REDWOOD CITY, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on January 15, 2016, the compensation committee of the...
-
REDWOOD CITY, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on January 4, 2016, the compensation committee of the...
-
Veltassa is the first FDA-approved medicine for hyperkalemia in more than 50 years Veltassa will be distributed to patients via two nationally-recognized specialty pharmaciesHospitals will receive...
-
REDWOOD CITY, Calif., Dec. 17, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on December 15, 2015, the compensation committee of the...
-
REDWOOD CITY, Calif., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on December 1, 2015, the compensation committee of the...
-
REDWOOD CITY, Calif., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the Oppenheimer 26th...